OCGN · Ocugen, Inc. · Webcasts, Transcripts & Audio
$0.81
-0.01 (-0.80%)
At close · Nov 6
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“After evaluating these conditions and management’s plans, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Nov 4, 2026
Market Cap
$294.01M
Shares
339.31M
Volume · Nov 5
7.15M
Avg daily vol (3M)
6.56M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ocugen, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Ocugen, Inc. (OCGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-12
Ocugen, Inc. (OCGN) November 12, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript
Revenue
$1.95M
▲ 11.4% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-11
Ocugen, Inc. (OCGN) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Confident tone
Regulatory milestones and BLAs
Cash runway and financing
Clinical trial progress and data readouts
Revenue
$1.49M
▲ 8.4% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Ocugen, Inc. (OCGN) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Confident tone
OCU400 for retinitis pigmentosa (RP)
Clinical milestones and timeline catalysts
OCU410ST for Stargardt disease
Revenue
$1.53M
▲ 3.5% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript
Confident tone
OCU410 (GA) Phase 2 data and Phase 3 initiation
Rolling BLA submission for OCU400 in 2026
OCU400 Phase 3 Limelight trial enrollment complete
Revenue
−$193,000*
▼ 125.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript
Confident tone
OCU400 Phase 3 retinitis pigmentosa
Clinical trial enrollment and timelines
OCU410 geographic atrophy / dry AMD
Revenue
$1.75M
▲ 54.2% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Confident tone
OCU400 gene therapy for retinitis pigmentosa
OCU410 for geographic atrophy / dAMD
Regulatory designations and agency interactions
Revenue
$1.37M
▲ 20.3% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
Confident tone
OCU410 dry AMD / geographic atrophy
OCU400 RP gene therapy program
Regulatory alignment with FDA and EMA
Revenue
$1.48M
▲ 46.1% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-05
Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript
Confident tone
OCU410 Dry AMD / Geographic Atrophy
OCU410ST Stargardt Disease
OCU400 Retinitis Pigmentosa Phase 3
Revenue
$764,000*
▼ 45.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Confident tone
OCU410 for Geographic Atrophy (ArMaDa Trial)
OCU410ST for Stargardt Disease (GARDian Trial)
OCU400 Phase 3 liMeliGhT Clinical Trial for RP
Revenue
$1.14M
▼ 69.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ocugen, Inc. (OCGN) Q2 2024 Earnings Call Transcript
Confident tone
OCU400 Phase 3 RP program
OCU410 geographic atrophy / dry AMD
Expanded Access Program for RP
Revenue
$1.14M
▲ 135.3% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
Confident tone
OCU400 Phase III liMeliGhT trial for RP/LCA
OCU410/Ocu410ST for dry AMD and Stargardt
Cell therapy platform and NeoCart
Revenue
$1.01M
▲ 128.9% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-04-02
Ocugen, Inc. (OCGN) Q4 2023 Earnings Call Transcript
Positive tone
OCU400 Phase III trial
FDA alignment and designations
OCU410 and OCU410ST programs
Revenue
$1.41M*
▲ 60.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Ocugen, Inc. (OCGN) Q3 2023 Earnings Call Transcript
Revenue
$3.70M
▲ 693.8% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-22
Ocugen, Inc. (OCGN) Q2 2023 Earnings Call Transcript
Revenue
$485,000
▼ 24.6% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Ocugen, Inc. (OCGN) Q1 2023 Earnings Call Transcript
Revenue
$443,000
▼ 11.4% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Ocugen, Inc. (OCGN) Q4 2022 Earnings Call Transcript
Revenue
$879,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Ocugen, Inc. (OCGN) Q3 2022 Earnings Call Transcript
Revenue
$466,000
Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-05
Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Revenue
$643,000
Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript
Revenue
$500,000
Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-25
Ocugen, Inc. (OCGN) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-06
Ocugen, Inc. (OCGN) Q2 2021 Earnings Call Transcript
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript
Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-18
Ocugen, Inc. (OCGN) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-08-14
Ocugen, Inc. (OCGN) Q2 2020 Earnings Call Transcript
Revenue
$43,000
Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-27
Ocugen, Inc. (OCGN) Q4 2019 Earnings Call
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1372299
CUSIP
67577C105
13F (30d)
57 filings
44 filers
Visit website
Investor relations